Interest in rare disease (RD) therapies continues to rise, with many established companies incorporating RD therapies into their portfolios for the first time. This paper:

  • Describes the special challenges associated with distributing RD products
  • Outlines the key steps and deliverables for developing and implementing supply chains for RD therapies
  • Summarizes the pitfalls that biopharma companies must avoid when working to establish reliable supply chains in rare diseases.